A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)
Latest Information Update: 14 Jul 2022
At a glance
- Drugs Enzalutamide (Primary) ; Mifepristone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Feb 2022 Primary endpoint of PSA progression-free survival has not been met, according to results published in the Clinical Cancer Research.
- 02 Feb 2022 Results published in the Clinical Cancer Research
- 15 Feb 2020 Status changed from recruiting to discontinued as per results presented at the 2020 Genitourinary Cancers Symposium.